(Fighting against New Coronary Pneumonia) The first sequential clinical trial of the new coronavirus inactivated vaccine of the Omicron strain was launched in China
China News Agency, Beijing, May 9. Sinopharm Group China Bio-Beijing Institute of Biological Products launched a sequential clinical trial of the new coronavirus inactivated vaccine against the new coronavirus in China's Hunan Province on May 9.
This is the first time that a sequential clinical study of the new crown vaccine has been carried out among the population who have been vaccinated with the new crown vaccine after the China Bio-Omicron strain new crown vaccine started blank population vaccination in Hangzhou, Zhejiang Province on May 1.
According to reports, this is the world's first sequential clinical trial with the largest number of people, the earliest start-up, and a comprehensive design of the new coronavirus inactivated vaccine of the Omicron strain.
This clinical study adopts a randomized, double-blind, and controlled study design. People aged 18 and over who have been vaccinated with 2 or 3 doses of the new crown vaccine are vaccinated at different intervals and in different dose sequences to evaluate the elimination of the new crown virus of the new crown virus of the omicron strain. Safety and immunogenicity of live vaccines.
When attending the clinical trial kick-off meeting at the Beijing venue, Yang Xiaoming, chairman of China Biotechnology, said in his speech that on the basis of the prototype inactivated vaccine of the new crown that had been marketed in the early stage, Sinopharm China Biotechnology introduced the Omicron variant strain from the University of Hong Kong for the first time. , On December 9, 2021, the research and development of the Omicron strain vaccine was quickly launched.
The clinical study launched today will evaluate the safety and immunogenicity of the vaccine in humans.
Zhang Yuntao, Chief Scientist and Vice President of China Biotechnology, said that China Biotechnology has systematically completed the preclinical research on the new crown inactivated vaccine of the Ormicon strain, and carried out in vitro cross-neutralization experiments with various new crown mutants.
The results of the study showed that the new crown vaccine of the Omicron strain can produce high titer neutralizing antibodies against the Omicron strain and various variant strains.
Zhang Yuntao said that more than 4,000 people are planned to be enrolled in this clinical study, which will evaluate the immunogenicity and safety of the new crown vaccine of Chronomicron strain after vaccination, and observe the best immunization procedures and doses in the future. It is currently the largest scale in the world. The clinical study of the new crown vaccine against the Ormicon strain.
It is known that on May 1, the clinical study of the new crown vaccine of Omicron strain of China Bio-Beijing Institute of Biological Products in blank population was officially launched in Hangzhou, Zhejiang.
China Bio-Omicron strain new crown vaccine has thus become the world's first inactivated vaccine against the new coronavirus strain of Omicron strain to enter clinical trials.
(Finish)